AI-generated summary
This narrative review examines neuroinflammation as a shared mechanism across brain disorders and the biological rationale for photobiomodulation, a low-intensity red to near-infrared light therapy. The authors report consistent preclinical evidence of multi-target anti-inflammatory effects. Clinical findings are described as early stage, with encouraging results in Alzheimer's disease and multiple sclerosis but mainly negative primary outcomes in Parkinson's disease and major depressive disorder.
- Who or what was studied
- unclear
- Limits stated in the abstract
- The authors state that clinical investigation remains at an early stage and that further research is needed to optimize parameters and determine clinical efficacy.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on frontiersin.org.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Neuroinflammation, Reactive oxygen species, Cytochrome c oxidase, Oxidative stress, Neurotechnology, Near-infrared. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.